Orthocell Ltd
ASX:OCC

Watchlist Manager
Orthocell Ltd Logo
Orthocell Ltd
ASX:OCC
Watchlist
Price: 0.615 AUD 0.82% Market Closed
Market Cap: 147.1m AUD
Have any thoughts about
Orthocell Ltd?
Write Note

P/E
Price to Earnings

-20.5
Current
-12.2
Median
22.7
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-20.5
=
Market Cap
147.1m AUD
/
Net Income
-7.2m AUD
All Countries
Close
Market Cap P/E
AU
Orthocell Ltd
ASX:OCC
147.1m AUD -20.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -181 004.1
US
Abbvie Inc
NYSE:ABBV
312.7B USD 61.5
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 37.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD -241.6
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 891.9
US
Epizyme Inc
F:EPE
94.1B EUR -472
AU
CSL Ltd
ASX:CSL
133.6B AUD 32.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 17.8
US
Seagen Inc
F:SGT
39.3B EUR -54.6
NL
argenx SE
XBRU:ARGX
34.5B EUR -129.9
Earnings Growth
AU
Orthocell Ltd
ASX:OCC
Average P/E: 208.3
Negative Multiple: -20.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-14.5
2-Years Forward
P/E
-304.5
3-Years Forward
P/E
N/A

See Also

Discover More